Compare MPAA & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPAA | CABA |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.7M | 319.6M |
| IPO Year | 2007 | 2019 |
| Metric | MPAA | CABA |
|---|---|---|
| Price | $15.53 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.50 | $14.50 |
| AVG Volume (30 Days) | 148.5K | ★ 4.1M |
| Earning Date | 06-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 162.63 | 10.26 |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $789,806,000.00 | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $24.05 | ★ N/A |
| Revenue Growth | ★ 4.28 | N/A |
| 52 Week Low | $9.29 | $1.26 |
| 52 Week High | $18.12 | $4.23 |
| Indicator | MPAA | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 69.74 | 44.54 |
| Support Level | $15.14 | $2.74 |
| Resistance Level | $16.13 | $3.34 |
| Average True Range (ATR) | 0.99 | 0.22 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 96.10 | 45.08 |
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts, test solutions, and diagnostic equipment. Its replacement parts are mainly sold to automotive retail chain stores, warehouse distributors across North America, and automobile manufacturers for aftermarket and warranty replacement programs. The Company's test solutions and diagnostic equipment serve the automotive component and powertrain testing market. Its product portfolio includes rotating electrical products such as alternators and starters; brake-related products including brake calipers, brake rotors, brake pads, brake master cylinders, and wheel hub assemblies and bearings; and other products. Its segments are Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.